tradingkey.logo

Check Cap Ltd

CHEK
查看詳細走勢圖
1.610USD
0.000
收盤 12/19, 16:00美東報價延遲15分鐘
9.42M總市值
虧損本益比TTM

Check Cap Ltd

1.610
0.000
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

0.00%

1月

+19.26%

6月

+118.01%

今年開始到現在

+62.64%

1年

+172.88%

查看詳細走勢圖

TradingKey Check Cap Ltd股票評分

單位: USD 更新時間: 2025-10-27

操作建議

當前估值合理,機構持股佔比非常高,目前股價在壓力位和支撐位之間,可以做區間波段操作。

Check Cap Ltd評分

相關信息

行業排名
298 / 501
全市場排名
559 / 4682
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Check Cap Ltd亮點

亮點風險
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入0.00美元
估值高估
公司最新PE估值-0.37,處於3年歷史高位
機構減倉
最新機構持股129.83K股,環比減少29.02%
活躍度增加
近期活躍度增加,過去20天平均換手率1.12

Check Cap Ltd新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Check Cap Ltd簡介

Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
公司代碼CHEK
公司Check Cap Ltd
CEOOvadia (Alex)
網址https://check-cap.com/

常見問題

Check Cap Ltd(CHEK)的當前股價是多少?

Check Cap Ltd(CHEK)的當前股價是 1.610。

Check Cap Ltd 的股票代碼是什麼?

Check Cap Ltd的股票代碼是CHEK。

Check Cap Ltd股票的52週最高點是多少?

Check Cap Ltd股票的52週最高點是3.130。

Check Cap Ltd股票的52週最低點是多少?

Check Cap Ltd股票的52週最低點是0.560。

Check Cap Ltd的市值是多少?

Check Cap Ltd的市值是9.42M。

Check Cap Ltd的淨利潤是多少?

Check Cap Ltd的淨利潤為-25.15M。

現在Check Cap Ltd(CHEK)的股票是買入、持有還是賣出?

根據分析師評級,Check Cap Ltd(CHEK)的總體評級為--,目標價格為--。

Check Cap Ltd(CHEK)股票的每股收益(EPS TTM)是多少

Check Cap Ltd(CHEK)股票的每股收益(EPS TTM)是-4.300。
KeyAI